Journal
CANCER CELL INTERNATIONAL
Volume 19, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12935-018-0720-y
Keywords
T cell receptor-engineered T cells; Immunotherapy; Leukemia
Categories
Funding
- National Natural Science Foundation of China [81770152, 91642111]
- Guangdong Provincial Basic Research Program [2015B020227003]
- Guangdong Provincial Applied Science and Technology Research & Development Program [2016B020237006]
- Guangzhou Science and Technology Project [201510010211, 20180710004, 201803040017]
Ask authors/readers for more resources
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy is an effective option for leukemia therapy. Recently, T cell immunotherapy studies have mainly focused on chimeric antigen receptor- and T cell receptor-engineered T cells. Clinical trials involving chimeric antigen receptor-engineered T cells have been a major breakthrough and became a novel therapy for leukemia. As another potential therapy for leukemia, clinical application of TCR-engineered T cells remains in its infancy. This article presents a review of the current status of anti-leukemia immunotherapy using leukemia antigen-specific TCR-engineered T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available